RS50553B - Derivati imidazola kao tafia-inhibitori - Google Patents

Derivati imidazola kao tafia-inhibitori

Info

Publication number
RS50553B
RS50553B RSP-2008/0107A RSP20080107A RS50553B RS 50553 B RS50553 B RS 50553B RS P20080107 A RSP20080107 A RS P20080107A RS 50553 B RS50553 B RS 50553B
Authority
RS
Serbia
Prior art keywords
formula
stands
compound
alkyl
cycloalkyl
Prior art date
Application number
RSP-2008/0107A
Other languages
English (en)
Serbian (sr)
Inventor
Andreas Lindenschmidt
Christopher Kallus
Holger Heitsch
Sven Grueneberg
Hauke Szillat
Original Assignee
Sanofi-Aventis Deutschland Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50553(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi-Aventis Deutschland Gmbh. filed Critical Sanofi-Aventis Deutschland Gmbh.
Publication of RS50553B publication Critical patent/RS50553B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RSP-2008/0107A 2004-04-22 2005-04-07 Derivati imidazola kao tafia-inhibitori RS50553B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla
PCT/EP2005/003630 WO2005105781A1 (de) 2004-04-22 2005-04-07 Imidazol-derivate als tafia-inhibitoren

Publications (1)

Publication Number Publication Date
RS50553B true RS50553B (sr) 2010-05-07

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2008/0107A RS50553B (sr) 2004-04-22 2005-04-07 Derivati imidazola kao tafia-inhibitori

Country Status (34)

Country Link
EP (2) EP1864979B1 (cg-RX-API-DMAC10.html)
JP (1) JP4939401B2 (cg-RX-API-DMAC10.html)
KR (1) KR101162047B1 (cg-RX-API-DMAC10.html)
CN (1) CN100572376C (cg-RX-API-DMAC10.html)
AR (1) AR053302A1 (cg-RX-API-DMAC10.html)
AT (2) ATE523505T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005238144B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0510159A (cg-RX-API-DMAC10.html)
CA (1) CA2563401C (cg-RX-API-DMAC10.html)
CR (1) CR8650A (cg-RX-API-DMAC10.html)
CY (1) CY1108087T1 (cg-RX-API-DMAC10.html)
DE (2) DE102004020186A1 (cg-RX-API-DMAC10.html)
DK (1) DK1740569T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP066941A (cg-RX-API-DMAC10.html)
ES (1) ES2299026T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20080099T3 (cg-RX-API-DMAC10.html)
IL (1) IL178672A (cg-RX-API-DMAC10.html)
MA (1) MA28543B1 (cg-RX-API-DMAC10.html)
MY (1) MY140903A (cg-RX-API-DMAC10.html)
NI (1) NI200600217A (cg-RX-API-DMAC10.html)
NO (1) NO20065320L (cg-RX-API-DMAC10.html)
NZ (1) NZ550757A (cg-RX-API-DMAC10.html)
PE (1) PE20060172A1 (cg-RX-API-DMAC10.html)
PL (1) PL1740569T3 (cg-RX-API-DMAC10.html)
PT (1) PT1740569E (cg-RX-API-DMAC10.html)
RS (1) RS50553B (cg-RX-API-DMAC10.html)
RU (1) RU2375356C2 (cg-RX-API-DMAC10.html)
SI (1) SI1740569T1 (cg-RX-API-DMAC10.html)
TN (1) TNSN06341A1 (cg-RX-API-DMAC10.html)
TW (1) TWI359016B (cg-RX-API-DMAC10.html)
UA (1) UA87306C2 (cg-RX-API-DMAC10.html)
UY (1) UY28868A1 (cg-RX-API-DMAC10.html)
WO (1) WO2005105781A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200607668B (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ577312A (en) 2006-12-06 2012-02-24 Sanofi Aventis Urea and sulfamide derivatives as tafia inhibitors
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008100459A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
EP2262783A2 (en) * 2008-02-21 2010-12-22 Sanofi-Aventis Covalently binding imaging probes
MX2010012793A (es) * 2008-06-06 2010-12-14 Sanofi Aventis Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia.
AU2009310841A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having TAFIa inhibitory activity
US8865906B2 (en) * 2009-05-15 2014-10-21 Sanofi Process for the preparation of a compound useful as an inhibitor of TAFIa
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
KR20130006620A (ko) 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
SG10201502026XA (en) 2010-03-18 2015-05-28 Daiichi Sankyo Co Ltd Cycloalkyl-substituted imidazole derivative
WO2012062730A1 (en) 2010-11-11 2012-05-18 Sanofi Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
EP2782576B1 (en) * 2011-11-25 2016-05-18 Sanofi Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
EP2782575B1 (en) 2011-11-25 2016-04-20 Sanofi Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
US9156815B2 (en) 2011-11-25 2015-10-13 Sanofi Salt of (R)-3-(6-amino-pyridin-3-yl)-2-(1-Cyclohexyl-1H-imidazol-4-yl) ethyl propionate
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
RU2015156612A (ru) * 2013-06-10 2017-07-17 Санофи Макроциклические производные мочевины в качестве ингибиторов tafia, их получение и их применение в качестве фармацевтических средств
US20190117624A1 (en) 2016-03-29 2019-04-25 Daiichi Sankyo Company, Limited Therapeutic agent for inflammatory bowel diseases
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20012338A3 (cs) * 1998-12-24 2001-12-12 Fujisawa Pharmaceutical Co., Ltd. Imidazolové sloučeniny
WO2003013526A1 (en) 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
CA2472239A1 (en) 2002-01-22 2003-07-31 Pfizer Inc. 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases

Also Published As

Publication number Publication date
UY28868A1 (es) 2005-11-30
UA87306C2 (en) 2009-07-10
TW200602325A (en) 2006-01-16
ZA200607668B (en) 2008-03-26
KR20070007346A (ko) 2007-01-15
SI1740569T1 (sl) 2008-06-30
PT1740569E (pt) 2008-03-31
ES2299026T3 (es) 2008-05-16
CR8650A (es) 2007-12-04
HK1101823A1 (zh) 2007-10-26
NZ550757A (en) 2010-06-25
CA2563401A1 (en) 2005-11-10
ECSP066941A (es) 2006-12-20
DE102004020186A1 (de) 2005-11-17
HRP20080099T3 (en) 2008-03-31
EP1740569A1 (de) 2007-01-10
JP2007533672A (ja) 2007-11-22
EP1864979A1 (de) 2007-12-12
IL178672A (en) 2011-08-31
BRPI0510159A (pt) 2007-10-02
PL1740569T3 (pl) 2008-07-31
TNSN06341A1 (en) 2008-02-22
KR101162047B1 (ko) 2012-07-04
AU2005238144A1 (en) 2005-11-10
JP4939401B2 (ja) 2012-05-23
PE20060172A1 (es) 2006-03-31
MA28543B1 (fr) 2007-04-03
RU2375356C2 (ru) 2009-12-10
AU2005238144B2 (en) 2010-08-26
EP1740569B1 (de) 2008-02-20
NI200600217A (es) 2008-06-17
CN1950357A (zh) 2007-04-18
CN100572376C (zh) 2009-12-23
CY1108087T1 (el) 2014-02-12
AR053302A1 (es) 2007-05-02
IL178672A0 (en) 2007-02-11
TWI359016B (en) 2012-03-01
WO2005105781A1 (de) 2005-11-10
EP1864979B1 (de) 2011-09-07
RU2006141246A (ru) 2008-06-10
NO20065320L (no) 2007-01-12
ATE386737T1 (de) 2008-03-15
DK1740569T3 (da) 2008-06-02
CA2563401C (en) 2012-08-07
DE502005002927D1 (de) 2008-04-03
MY140903A (en) 2010-01-29
ATE523505T1 (de) 2011-09-15

Similar Documents

Publication Publication Date Title
EP1740569B1 (de) Imidazol-derivate als tafia-inhibitoren
JP6440690B2 (ja) シクロアルキル酸誘導体、その製造方法、およびその医薬適用
SK22099A3 (en) Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
MXPA03002294A (es) Compuestos de pirazol utiles como inhibidores de proteina cinasa.
CZ297544B6 (cs) Substituované N-[(aminoiminomethyl)-fenyl]propylamidy nebo N-[(aminomethyl)fenyl]propylamidy
US8044208B2 (en) Imidazole derivatives as inhibitors of TAFIa
EP2138482A1 (en) Bicyclic heterocyclic compound
CN101516834B (zh) 用作凝血因子IXa抑制剂的异丝氨酸衍生物
EP2548872A1 (en) Cyclopropanecarboxylic acid derivative
US6750225B2 (en) 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
BRPI0911538A2 (pt) Composição farmacêutica contendo um composto derivado de benzimidazol e uso do composto
ES2603302T3 (es) Imidazopiridazinas como inhibidores de PAR1, su obtención y empleo como medicamento
RU2446160C2 (ru) Тартратные производные для применения в качестве ингибиторов фактора свертывания крови ixa
SA03240142B1 (ar) 2،5- ثنائي مستبدل -3- حمض ميركابتوبينتانويك2,5-disubtitiuted-3- mercaptopentanoic acid
EP3818055B1 (en) Novel bronchodilating hetero-linked amides
CN102250099B (zh) 一类非肽类抗凝血酶抑制剂、其制法以及医药用途
US7863269B2 (en) Imino-imidazo-pyridine derivatives having antithrombotic activity
CN103420984B (zh) 作为前药的达比加群酯衍生物及其制备方法和用途
NZ250001A (en) Alkoxymethyl substituted pyridone biphenyls and medicaments
CA2884767A1 (en) Imidazopyridine derivatives
HK40047621A (en) Bronchodilating hetero-linked amides
HK40047621B (en) Bronchodilating hetero-linked amides
JPS61197557A (ja) インダン誘導体およびその製法
HK1180340A (en) Cyclopropanecarboxylic acid derivative
MXPA01000511A (en) Piperazinone derivatives and their uses